Key facts
- Kimer Med’s last known valuation is $27.4M.
- It has raised $11.5M; the latest was Early Stage VC ($8.5M) in Oct 2024.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Kimer Med
- ·The full record, as it builds
Funding rounds
No funding rounds for Kimer Med are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kimer Med
Operator of a biotech company intended for the development of novel, broad-spectrum antivirals. The company specializes in developing and testing and aims to bring to market broad-spectrum drugs for both humans and animals, enabling healthcare industries to treat viral diseases for pandemic protection.
- Sector
- Healthcare
- HQ
- Nelson, New Zealand
- Founded
- 2020
- Employees
- 7
- Website
- kimermed.co.nz/
- Ownership
- Privately Held (backing)
Kimer Med doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kimer Med shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kimer Med in its N-PORT filings yet. We sweep new filings monthly.